Phase II Clinical Trial Data

Dose-ranging study to examine the pharmacokinetics, safety, tolerability and efficacy of Cybis®  THC:CBD oil in adults with chronic back/neck pain

Non-randomised, single arm, open-label study of Cybis® 10:25 in patients with chronic, moderate to severe back or neck pain who received escalating doses of Cybis® 

28 patients underwent a screening visit, then seven clinic visits (Day 1, 2, 8, 15, 22, 29, and 35)

Cybis®  was administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily

Total duration of dosing was 28 days